Virtus Fund Advisers’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $109K | Buy |
795
+27
| +4% | +$3.69K | 0.34% | 25 |
|
|
2024
Q3 | $88.5K | Hold |
768
| – | – | 0.36% | 34 |
|
|
2024
Q2 | $106K | Buy |
768
+19
| +3% | +$2.62K | 0.42% | 20 |
|
|
2024
Q1 | $103K | Buy |
749
+62
| +9% | +$8.55K | 0.37% | 30 |
|
|
2023
Q4 | $90.5K | Buy |
687
+285
| +71% | +$37.6K | 0.56% | 22 |
|
|
2023
Q3 | $45.2K | Buy |
+402
| New | +$45.2K | 0.32% | 53 |
|
|
2017
Q4 | $1.38M | Buy |
17,726
+12,419
| +234% | +$963K | 0.01% | 268 |
|
|
2017
Q3 | $325K | Sell |
5,307
-330
| -6% | -$20.2K | ﹤0.01% | 335 |
|
|
2017
Q2 | $263K | Sell |
5,637
-168
| -3% | -$7.84K | ﹤0.01% | 377 |
|
|
2017
Q1 | $251K | Sell |
5,805
-3,106
| -35% | -$134K | ﹤0.01% | 394 |
|
|
2016
Q4 | $345K | Sell |
8,911
-3,059
| -26% | -$118K | ﹤0.01% | 375 |
|
|
2016
Q3 | $606K | Hold |
11,970
| – | – | 0.01% | 308 |
|
|
2016
Q2 | $542K | Hold |
11,970
| – | – | ﹤0.01% | 328 |
|
|
2016
Q1 | $473K | Sell |
11,970
-2,540
| -18% | -$100K | ﹤0.01% | 349 |
|
|
2015
Q4 | $821K | Sell |
14,510
-152
| -1% | -$8.6K | 0.01% | 299 |
|
|
2015
Q3 | $583K | Sell |
14,662
-43,896
| -75% | -$1.75M | 0.01% | 332 |
|
|
2015
Q2 | $2.8M | Sell |
58,558
-816
| -1% | -$39K | 0.02% | 278 |
|
|
2015
Q1 | $2.36M | Sell |
59,374
-5,524
| -9% | -$219K | 0.02% | 308 |
|
|
2014
Q4 | $1.45M | Buy |
64,898
+314
| +0.5% | +$7.02K | 0.01% | 357 |
|
|
2014
Q3 | $1.01M | Sell |
64,584
-6,020
| -9% | -$94.3K | 0.01% | 396 |
|
|
2014
Q2 | $1.05M | Buy |
+70,604
| New | +$1.05M | 0.01% | 445 |
|